CAS No. |
62067-29-2 |
中文名称 |
溴四氢小檗碱 |
英文名称 |
Bromotetrandrine |
别名 |
Bromotetrandrine;5-Bromotetrandrine;BrTet;W 198;W198;W-198;16H-1,24:6,9-Dietheno-11,15-metheno-2H-pyrido[2',3':17,18][1,11]dioxacycloeicosino[2,3,4-ij]isoquinoline, 20-bromo-3,4,4a,5,16a,17,18,19-octahydro-12,21,22,26-tetramethoxy-4,17-dimethyl-, (4aS,16aS)- |
标准英文名 |
(11S,31S)-35-bromo-16,36,37,54-tetramethoxy-12,32-dimethyl-11,12,13,14,31,32,33,34-octahydro-2,6-dioxa-1(7,1),3(8,1)-diisoquinolina-5(1,3),7(1,4)-dibenzenacyclooctaphane |
分子式 |
C38H41BrN2O6 |
分子量 |
701.66
|
精确分子量 |
700.21
|
SMILES |
CN1CCC2=CC(OC)=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(C[C@H]6C7=C(CCN6C)C(Br)=C(C(OC)=C7O3)OC)=C5)OC |
标准SMILES |
CN1CCC2C(Br)=C(OC)C(OC)=C3OC4C=C5[C@H](CC6C=CC(=CC=6)OC6C=C(C[C@H]1C=23)C=CC=6OC)N(C)CCC5=CC=4OC |
用途 |
Bromotetrandrine is a potent inhibitor of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR); it exhibits significant MDR reversal activity in vitro and in vivo, potentially by inhibiting P-gp overexpression and enhancing intracellular accumulation of anticancer drugs; it is a brominated derivative of tetrandrine and holds promise as an MDR modulator in cancer therapy. |
InChIKey |
ANJMFZGRGHQXMA-VMPREFPWSA-N |